New non-invasive (bioprognostic) tests FibroAktiTest, Fibromax
Last reviewed: 20.11.2021
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
In January 2007, the French Ministry of Health recognized FibroTest as a real alternative to liver biopsy. This was the reason for the simultaneous implementation of these tests in a number of countries.
FibroTest displays the stages of fibrosis (T0, P1, P2, R3, P4) and the degree of necro-inflammatory process (A0, A1, A2, A3) according to the internationally accepted METAVIR system, which provides an easy and universal interpretation of the results. These tests allow to obtain an accurate quantitative and qualitative assessment of fibrosis, steatosis and necroinflammatory changes in the liver at all stages, regardless of localization, which eliminates the possibility of an error in the local study of the material, obtaining! O method of puncture biopsy.
Bioprognostic tests:
- FibroActi Test is a combination of FibroTest and ActiTest (FibroTest diagnoses liver fibrosis, with the help of ActiTest, viral necroinflammatory activity is assessed);
- FibroMax is a combination of five non-invasive tests: FibroTest, ActiTest, SteatoTest, NeshTest, AshTest [with the help of SteatoTest, he is diagnosed with liver steatosis mainly due to a violation of ALT and GGTP content; with the help of AshTest - heavy alcoholic steatohepatitis (ASH); with NeshTest, nonalcoholic steatohepatitis (NASH) in patients with overweight, insulin resistance, diabetes mellitus, or hyperlipidemia.
When carrying out FibroTest and FibroMax, mathematical formulas are used that independently test each parameter to obtain the test result. Each of these parameters separately serves as an indicator of hepatitis.
The algorithm also includes variables of age, weight, height and sex. This makes it possible to diagnose with greater accuracy when carrying out FibroTest and FibroMax.
A set of biochemical indicators included in the tests Fibrotest and FibroMax
|
B / x, the indicator |
FibroTest |
FibroMax |
|
A-2-macroglobulin |
+ |
+ |
|
Haptoglobin |
+ |
+ |
|
Apolipoirothein A1 |
+ |
+ |
|
GGT |
+ |
+ |
|
Total bilirubin |
+ |
+ |
|
AJTT |
+ |
+ |
|
ACT |
- |
+ |
|
Fasting blood glucose |
- |
+ |
|
Triglycerides |
- |
+ |
|
Total cholesterol |
- |
+ |
Assessment of the stage of fibrosis with FibroTest, expressed in accordance with generally accepted international systems
|
FibroTest |
Evaluation of stages of fibrosis | ||
|
METAVIR |
Knodell |
Ishak | |
|
0.75-1.00 |
F4 |
F4 |
F6 |
|
0.73-0.74 |
F3-F4 |
F3-F4 |
F5 |
|
0.59-0.72 |
F3 |
F3 |
F4 |
|
0.49-0.58 |
F2 |
F1-F3 |
F3 |
|
0.32-0.48 |
F1-F2 |
F1-F3 |
F2-F3 |
|
0.28-0.31 |
F1 |
F1 |
F2 |
|
0.22-0.27 |
F0-F1 |
F0-F1 |
F1 |
|
0.00-0.21 |
F0 |
F0 |
F0 |
Thus, FibroTest is an alternative to liver biopsy in patients with chronic hepatitis B and C, alcohol and non-alcoholic liver disease. Diagnostic value is confirmed for both transitional and extreme stages.